| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 22.4% | +11.5% | $119M | $12.1M | 11.9M | +11.4% | RA Capital Management, L.P. | Jun 4, 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 7.8% | $31.4M | 3.94M | BVF PARTNERS L P/IL | Dec 31, 2024 | |||
| Canaan XI L.P. | 7.4% | $29.7M | 3.73M | Canaan XI L.P. | Dec 31, 2024 | |||
| TCG Crossover GP I, LLC | 5.7% | $23.1M | 2.9M | TCG Crossover GP I, LLC | Feb 27, 2025 | |||
| Vestal Point Capital, LP | 5.4% | $22.9M | 2.88M | Vestal Point Capital, LP | Mar 31, 2025 | |||
| JANUS HENDERSON GROUP PLC | 5.4% | +6% | $28.8M | $1.65M | 2.86M | +6.05% | JANUS HENDERSON GROUP PLC | Jun 30, 2025 |
| COMMODORE CAPITAL LP | 5.2% | $21.9M | 2.75M | Commodore Capital LP | May 7, 2025 | |||
| FMR LLC | 3.2% | $13.6M | 1.71M | FMR LLC | Mar 31, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1.9K | $26.2K | +$2.02K | $14.00 | 4 |
| 2025 Q2 | 56.6M | $542M | +$28.8M | $9.57 | 120 |
| 2025 Q1 | 53.6M | $500M | +$34.7M | $9.30 | 116 |
| 2024 Q4 | 48.6M | $676M | -$145M | $13.90 | 112 |
| 2024 Q3 | 47.1M | $1.11B | +$8.15M | $23.51 | 96 |
| 2024 Q2 | 46.8M | $749M | -$1.81M | $15.99 | 76 |
| 2024 Q1 | 46.9M | $768M | +$182M | $16.40 | 75 |
| 2023 Q4 | 35.8M | $495M | -$10M | $13.85 | 62 |
| 2023 Q3 | 36.5M | $502M | +$3.66M | $13.77 | 59 |
| 2023 Q2 | 36.2M | $616M | +$7.68M | $17.03 | 58 |
| 2023 Q1 | 35.7M | $573M | +$8.46M | $16.07 | 50 |
| 2022 Q4 | 35.2M | $268M | -$5.16M | $7.60 | 45 |
| 2022 Q3 | 35.7M | $314M | -$405K | $8.79 | 43 |
| 2022 Q2 | 35.7M | $255M | -$3.41M | $7.15 | 43 |
| 2022 Q1 | 36.1M | $387M | +$8.96M | $10.70 | 46 |
| 2021 Q4 | 35.2M | $494M | +$13.7M | $14.07 | 45 |
| 2021 Q3 | 26.1M | $457M | +$456M | $17.59 | 25 |